DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · IEX Real-Time Price · USD
3.410
+0.160 (4.92%)
Jul 22, 2024, 11:21 AM EDT - Market open
DiaMedica Therapeutics Employees
As of December 31, 2023, DiaMedica Therapeutics had 19 total employees, including 18 full-time and 1 part-time employees. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,014,211
Market Cap
142.76M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amylyx Pharmaceuticals | 384 |
Cellectis | 221 |
Electromed | 170 |
EUDA Health Holdings | 106 |
Invivyd | 95 |
Vigil Neuroscience | 69 |
Corvus Pharmaceuticals | 28 |
PDS Biotechnology | 25 |
DMAC News
- 11 days ago - DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
- 21 days ago - DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement - Business Wire
- 26 days ago - DiaMedica Therapeutics Announces $11.8 Million Private Placement - Business Wire
- 26 days ago - DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results - Business Wire
- 2 months ago - DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 - Business Wire
- 3 months ago - DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke - Business Wire
- 4 months ago - DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results - Business Wire